Yuanyi Wise Tech (Ningbo) Ltd. has prepared and tested new tricyclic compounds acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12V mutant) interaction inhibitors potentially useful for the treatment of cancer.
Agomab Therapeutics NV has identified new TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors designed for use in the treatment of idiopathic pulmonary fibrosis.
Deepcure Inc. has synthesized new 3,4-dihydroquinoxalin-2(1H)-ones acting as bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors. As such, they are described as potentially useful for the treatment of autoimmune, cardiovascular disease, inflammatory disorders, multiple sclerosis, psoriasis, gout, obesity, and sepsis, among others.
Genosco Inc. has patented new molecular glue degraders comprising cereblon-binding agents acting as GSPT and/or Myc proto-oncogene protein (c-Myc) degradation inducers designed for use in the treatment of cancer.
Sanyou Biopharmaceuticals Co. Ltd. has prepared and tested new antibody-drug conjugates (ADCs) comprising an antibody or antigen-binding fragment targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to a cytotoxic agent through linker reported to be useful for the treatment of lung and stomach cancer.
Antibody-drug conjugates (ADCs) comprising an antibody targeting folate receptor α (FOLR1; FR-α) covalently linked to a cytotoxic drug have been described in a Shanghai Pharmaceuticals Holding Co. Ltd. patent and are reported to be potentially useful for the treatment of cancer.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has patented new crystalline salt forms of poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Vanderbilt University has identified new 1-heteroarylazetidine-3-heteroarylmethylcarboxamide 5-HT2B receptor antagonists reported to be useful for the treatment of myocardial infarction, systemic sclerosis and pulmonary arterial hypertension.
RSS